Biostem Technologies

Biostem Technologies Rule of 40

The Rule of 40 of Biostem Technologies (BSEM) as of Nov 1, 2026 is 1,719.27 %. In the previous year, Rule of 40 was 96.05 % — a change of 1,690.04% (higher).

Rule of 40

1,719.27 %

YoY

1,690.04%

Last updated:

Rule of 40 of Biostem Technologies is 2024 1,719.27 % . Rule of 40 of Biostem Technologies was 2023 96.05 % . It decreases by 1,690.04% higher compared to the previous year.

The Biostem Technologies Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2017
-1,515.61 USD
Jan 1, 2018
-554.00 USD
Jan 1, 2019
-57.22 USD
Jan 1, 2020
-77.19 USD
Jan 1, 2021
35.15 USD
Jan 1, 2022
-9.71 USD
Jan 1, 2023
96.05 USD
Jan 1, 2024
1,719.27 USD
The Biostem Technologies Rule of 40 history
YEARRule of 40YoY
1,719.27 %+1,690.04%
96.05 %-1,089.24%
-9.71 %-127.62%
35.15 %-145.54%
-77.19 %+34.91%
-57.22 %-89.67%
-554.00 %-63.45%
-1,515.61 %+382.59%
-314.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

Rule of 40 of Biostem Technologies is 1,719.27 % in 2024.

On Eulerpool you can find the complete historical development of Rule of 40 Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Biostem Technologies

All Key Metrics — Biostem Technologies